--------------------------------------------------------------------------------

Confidential
CONFIDENTIAL TREATMENT REQUESTED
 
UNDER 17 C.F.R §§ 200.80(B)4, AND 240.24B-2

EXHIBIT 10.2

AMENDMENT #1 TO HTT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT
 
This AMENDMENT #1 TO THE RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT
(this “Amendment”) is entered into and made effective as of the 9th day of
January, 2015 (the “Amendment Date”) by and between Isis Pharmaceuticals, Inc.,
a Delaware corporation, having its principal place of business at 2855 Gazelle
Court, Carlsbad, CA 92010 (“Isis”), and F. Hoffmann-La Roche Ltd, a Swiss
corporation, having its principal place of business at Grenzacherstrasse 124,
4070 Basel, Switzerland (“Roche Basel”) and Hoffmann-La Roche Inc.,  a New
Jersey corporation, having its principal place of business at 150 Clove Road,
Suite 8, Little Falls, New Jersey 07424 (“Roche Nutley”; Roche Basel and Roche
Nutley are collectively referred to as “Roche”).  Isis and Roche are each
referred to herein by name or as a “Party” or, collectively, as “Parties.”
 
RECITALS
 
Whereas, Isis and Roche are parties to the HTT Research, Development, Option and
License Agreement dated April 8th, 2013, as amended (the “Agreement”);
 
Whereas, Isis and Roche desire to amend the Agreement to clarify its rights and
obligations thereunder; and
 
Now, therefore, in consideration of the premises and mutual covenants herein
contained, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties, intending to be
legally bound, do hereby agree that Section 7.12 of the Agreement is amended by
replaced with the following:
 

7.12. No Challenge. If, during the Agreement Term, solely with respect to rights
to the [***] that are included (or, prior to Option exercise, are eligible to be
included) in a license granted to Roche under Section 4.1.1, Roche, its
Affiliates or Sublicensees, in the United States or any other country, (a)
commence or otherwise voluntarily determine to participate in (other than as may
be necessary or reasonably required to assert a cross-claim or a counter-claim
or to respond to a court request or order or administrative law request or
order) any action or proceeding, challenging or denying the enforceability or
validity of any claim within an issued patent or patent application within such
[***], or (b) direct, support or actively assist any other Person (other than as
may be necessary or reasonably required to assert a cross-claim or a
counter-claim or to respond to a court request or order or administrative law
request or order) in bringing or prosecuting any action or proceeding
challenging or denying the validity of any claim within an issued patent or
patent application within such [***], then unless, within thirty (30) days after
written notice from Isis, Roche rescinds any actions brought by Roche, its
Affiliates, or Sublicensees, Isis may, to the extent permitted under Applicable
Law, terminate this Agreement and the provisions of Section 10.4.1 and Section
10.4.2 will apply; [***].

 
1

--------------------------------------------------------------------------------

Confidential

Capitalized terms not otherwise defined herein will have the meanings given in
the Agreement.

* - * - * - *
 
[Signature page follows]
 
2

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by
their duly authorized representatives as of the Amendment Date.

Isis Pharmaceuticals, Inc.
     
By:
/s/ B. Lynne Parshall
   
Name:
B. Lynne Parshall
   
Title:
Chief Operating Officer
   
Date:
               
F. Hoffman-La Roche Ltd
     
By:
/s/ Dr. Christoph Sarry
By:
/s/ Stefan Arnold
Name:
Dr. Christoph Sarry
Name:
Stefan Arnold
Title:
Global Alliance Director
Title:
Head Legal Pharma
Date:
12 January 2015
           
Hoffman-La Roche Inc.
     
By:
/s/ John P Parise
   
Name:
John P Parise
   
Title:
Authorized Signatory
   
Date:
Jan 12, 2015
   

 
 
3

--------------------------------------------------------------------------------